Although the Framingham study and post hoc analysis of the Treating New Target (TNT) study revealed that low-density lipoprotein (LDL) variability increased the risk of CVD in subjects with or without CVD [10,11], somewhat conflicting results were found in Korean nationwide population-based cohort studies. Kim et al. [12] showed that total cholesterol variability increased the risk of myocardial infarction (MI), stroke, and all-cause mortality, and Park et al. [13] demonstrated that in statin-naïve healthy young people, the associations between lipid variability and risk of MI and stroke varied depending on the measure of lipid variability used. These controversial results might be caused by different study populations, lack of standardized variability indices, and diverse interval and number of blood lipid measurements. To date, in most studies regarding the relationship between lipid variability and CVD, the main emphasis has been on ischemic vascular insults. However, current studies focusing on other CVDs such as heart failure (HF) and atrial fibrillation (AF) have been published. In those studies, for the highest quartile in total cholesterol variability compared with the lowest quartile, the risk of HF and AF increased by 17% and 8%, respectively [14,15]. In a recent study published in Diabetes and Metabolism Journal, Park et al. [16] showed that, over the median follow-up of 3.7 years, coefficient of variation (CV) and variation independent of the mean of LDL-cholesterol and all the variability parameters of apolipoprotein B (apoB) were significantly associated with development of subclinical left ventricular diastolic dysfunction (LVDD). However, the mean of any lipid variability measurement was not associated with risk of LVDD. Furthermore, this association between CV in LDL and risk of LVDD did not significantly correlate with sex, increasing/decreasing trend from baseline, or use of stain and/or other lipid-modifying agents. Subclinical LVDD is an important structural risk factor for HF with preserved ejection fraction (HFpEF), mainly derived from insulin resistance [17]. HF, which is the most common cause of hospital admission in patients ≥65 years of age, has become a critical public health concern [18]. Due to the limitation in methods to reverse and cure HF, determining the risk factors for HF and applying a preventive strategy to high-risk subjects are important. Based on the present study, maintenance of stable LDL-cholesterol level might be helpful for preventing HF, and monitoring of LDL-cholesterol variability provided additional information regarding the risk of HF. Notably, LDL-cholesterol and apoB variability were closely associated with very early structural and functional changes in the heart, preceding clinical manifestation. As the authors mentioned, due to the relative short-term follow-up period for the apparently healthy population, mean LDL-cholesterol and apoB level were not associated with LVDD. This results also indicates that LDL-cholesterol variability was a very sensitive marker for LVDD. A commonly cited mechanism to explain the association between high variability in biological parameters and poor clinical outcome is that variability might reflect general frailty and only an epiphenomenon underlying an unhealthy systemic condition. However, the present study results showed an association of lipid variability with the very early phase of diastolic dysfunction, the subclinical outcome, within 3.7 years. Furthermore, this positive relationship was observed in the statin non-user subgroup during the period of variability check-up, which excludes the possibility that non-adherence to statin was the underlying mechanism between LDL-C variability and subclinical LVDD. High cholesterol variability induces fluctuation of plaque composite, making subjects more vulnerable to rupture [19], which is a main underlying mechanism explaining the relationship of cholesterol variability with ischemic CVD. However, in the present study, only three subjects developed regional wall motion abnormality consistent with ischemic heart disease, indicating that the influence of cholesterol variability on unstable plaque formation could not be the cause. The most reliable theory to explain the study results is that higher LDL-cholesterol or apoB variability is associated with endothelial dysfunction, oxidative stress, and inflammatory processes, which are considered to play a crucial role in the pathogenesis of LVDD and HFpEF. Therefore, to confirm the present study results, further research to clarify the underlying molecular mechanism and well-designed randomized controlled clinical trial with the intervention to stabilize LDL-cholesterol near the lower level should be performed. The results showing significant association with very early structural and functional changes in the heart prior to clinical manifestation indicate that lipid variability directly affects the pathogenesis of HF.